Oregon is currently home to 1222 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359
Recruiting
Primary Objectives: * To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable. * To evaluate the time-course of AD and selected atopic comorbidities. Secondary Objectives: * To characterize disease burden and unmet need. * To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinua... Read More
Gender:
ALL
Ages:
Between 0 years and 11 years
Trial Updated:
01/16/2025
Locations: Cyn3rgy Research & Development Site Number : 8400023, Gresham, Oregon
Conditions: Dermatitis Atopic
Register for Updates
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
NCT06040099
Recruiting
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
01/15/2025
Locations: Research Site, Portland, Oregon
Conditions: Hepatocellular Carcinoma (HCC)
Register for Updates
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277
Recruiting
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Research Site, Portland, Oregon
Conditions: Metastatic Non-small Cell Lung Cancer
Register for Updates
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment with Paclitaxel (Phase II)
NCT05751668
Recruiting
This phase II trial tests the safety, side effects, and best dose of monosialotetrahexosylganglioside (GM1) and whether it works in reducing or preventing chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) who are receiving treatment with paclitaxel. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of cancer cells, either by killing th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Legacy Mount Hood Medical Center, Gresham, Oregon
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma
Register for Updates
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
NCT05685004
Recruiting
This randomized study is designed to compare the combination of TVI-Brain-1 immunotherapy and standard therapy compared to standard therapy alone as a treatment for newly diagnosed MGMT unmethylated glioblastoma patients. The patients' own cancer cells collected after surgery are combined into a vaccine to produce an immune response that significantly increases the number of cancer neoantigen-specific effector T cell precursors in the patient's body. These cancer neoantigen-specific T cells are... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/15/2025
Locations: Providence St. Vincent, Portland, Oregon
Conditions: Glioblastoma Multiforme of Brain
Register for Updates
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
NCT05329766
Recruiting
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Providence Cancer Institute Franz Clinic, Portland, Oregon
Conditions: Gastrointestinal Tract Malignancies
Register for Updates
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
NCT05256940
Recruiting
The purpose of this project is to conduct a randomized control trial with 470 Veterans to examine the impact of a revised version of Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) on risk for suicide attempts and suicidal ideation when compared to high quality usual care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: VA Portland Health Care System, Portland, OR, Portland, Oregon
Conditions: Suicide, Attempted, Suicidal Ideation
Register for Updates
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204
Recruiting
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Oregon Health Sciences Uni, Portland, Oregon
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
NCT05006794
Recruiting
This is a Phase I open-label, multi-center study of zamzetoclax (formerly GS-9716) tested either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies. Primary objectives are to define the maximum tolerated dose (MTD) or maximum administered dose of zamzetoclax, and characterize the safety and tolerability of zamzetoclax as monotherapy and in combination with anti-cancer therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Oregon Health Oregon Health & Sciences University-Knight Cancer Institute, Portland, Oregon
Conditions: Solid Malignancies
Register for Updates
Sleep for Stroke Management and Recovery Trial
NCT03812653
Recruiting
The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Providence St. Vincent Medical Center, Portland, Oregon
Conditions: Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
Register for Updates
Accelerated Flap Coverage in Severe Lower Extremity Trauma
NCT06293469
Recruiting
The goal of this randomized controlled trial is to determine if accelerated flap coverage compared to standard flap coverage timing leads to improved infection-related complications in patients with open fractures and/or dislocations below the knee. Eligible patients will be randomized to receive either a flap within a goal of 72 hours of injury or standard of care flap timing for the institution. The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomiz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Open Tibia Fracture, Open Dislocation of Ankle, Extremity Fracture Lower, Extremity Injuries Lower
Register for Updates
Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)
NCT06133231
Recruiting
Evaluate feasibility and acceptability of recruiting Black and Hispanic families for an open label clinical trial of multinutrients while collecting real-time parent-reported child behavior data and collecting at-home biospecimens to explore their potential as biomarkers, in a study of pediatric ADHD.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
01/14/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Attention Deficit/Hyperactivity Disorder, Emotional Dysfunction, Irritable Mood
Register for Updates